Abstract: Disclosed herein is the cosmetic use, as a desquamating agent, of at least one (dihydro)jasmonic acid derivative of a given formula. Further disclosed herein is a cosmetic method for smoothing the visible and/or tactile irregularities of the skin surface, for example, for smoothing wrinkles and fine lines and/or skin spots and/or smoothing the skin, comprising topically applying, to the skin, a composition comprising, in a physiologically acceptable medium, at least one (dihydro)jasmonic acid derivative and glycerine. Other embodiments disclosed herein are novel (dihydro)jasmonic acid derivatives.
Abstract: Novel compounds of the formula I in which R, X and n are as defined herein, are inhibitors of tyrosine kinase and can be employed for the treatment of tumours, for neuroprotection and for protection of the stress proteins of the skin.
Abstract: The present invention relates to certain glucose-based compounds that have an affinity to P-selectin. Further, the invention relates to the use of these glucose-based compounds for the preparation of pharmaceutical compositions for the treatment of disorders associated with P-selectin, to conjugates, pharmaceutical carriers and drug delivery systems comprising said compounds, and to a method for determining whether a compound is capable of binding to P-selectin.
Type:
Grant
Filed:
October 13, 2003
Date of Patent:
December 4, 2007
Assignee:
Astellas Pharma Europe B.V.
Inventors:
Chantal Catharina Maria Appeldoorn, Erik Anna Leonardus Biessen, Thomas Jacobus Maria Molenaar, Theodorus Josephus Cornelis Van Berkel
Abstract: The invention describes compositions and kits comprising 4-aza-4-(2-methyl-2-sulfanylpropyl) tricyclo(5.2.1.0<2,6>)dec-8-ene-3,5-dione; 4-aza-4-(2-methyl-2-(nitrosothio)propyl) tricyclo(5.2.1.0<2,6>)dec-8-ene-3,5-dione; 4-{1-methyl-1-((2,4,6-trimethoxyphenyl)methylthio)ethyl}-1,3-oxazolidin-2-one; 2-aAmino-3-methyl-3-((2,4,6-trimethoxyphenyl)methylthio)butan-1-ol; 4-(1-methyl-1-(nitrosothio)ethyl)-1,3-oxazolidin-2-one; or pharmaceutically acceptable salts thereof. The compositions of the invention can further comprise at least one penetration enhancer, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent.
Type:
Grant
Filed:
February 20, 2004
Date of Patent:
July 3, 2007
Assignee:
NitroMed, Inc.
Inventors:
Przemyslaw A. Marek, Andzrej M. Trocha, Chia-En Lin, Ramani R. Ranatunge, Stewart K. Richardson
Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
Type:
Grant
Filed:
December 19, 2002
Date of Patent:
May 1, 2007
Assignees:
Pharmasset, Inc., Emory University, Beth Israel Deaconess Medical Center
Inventors:
Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson